- Home
- CVKD vs BNR Comparison
CVKD vs BNR Comparison
Compare CVKD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- BNR
- Stock Information
- Founded
- CVKD 2022
- BNR 2014
- Country
- CVKD United States
- BNR China
- Employees
- CVKD N/A
- BNR N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- BNR Medical Specialities
- Sector
- CVKD Health Care
- BNR Health Care
- Exchange
- CVKD Nasdaq
- BNR Nasdaq
- Market Cap
- CVKD 29.5M
- BNR 38.3M
- IPO Year
- CVKD 2023
- BNR 2020
- Fundamental
- Price
- CVKD $10.54
- BNR $6.47
- Analyst Decision
- CVKD Strong Buy
- BNR
- Analyst Count
- CVKD 1
- BNR 0
- Target Price
- CVKD $32.00
- BNR N/A
- AVG Volume (30 Days)
- CVKD 27.7K
- BNR 53.8K
- Earning Date
- CVKD 08-11-2025
- BNR 08-21-2025
- Dividend Yield
- CVKD N/A
- BNR N/A
- EPS Growth
- CVKD N/A
- BNR N/A
- EPS
- CVKD N/A
- BNR N/A
- Revenue
- CVKD N/A
- BNR $72,112,038.00
- Revenue This Year
- CVKD N/A
- BNR $136.32
- Revenue Next Year
- CVKD N/A
- BNR N/A
- P/E Ratio
- CVKD N/A
- BNR N/A
- Revenue Growth
- CVKD N/A
- BNR 0.53
- 52 Week Low
- CVKD $5.70
- BNR $2.18
- 52 Week High
- CVKD $22.90
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- CVKD 37.37
- BNR 60.79
- Support Level
- CVKD $11.25
- BNR $5.81
- Resistance Level
- CVKD $11.88
- BNR $9.48
- Average True Range (ATR)
- CVKD 0.77
- BNR 0.90
- MACD
- CVKD -0.03
- BNR 0.12
- Stochastic Oscillator
- CVKD 2.95
- BNR 45.86
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.